Page last updated: 2024-11-13

bms 708163

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BMS 708163: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46883536
CHEMBL ID1090771
CHEBI ID177493
SCHEMBL ID310019
MeSH IDM0552493

Synonyms (65)

Synonym
HY-50845
CHEBI:177493
avagacestat
1146699-66-2
(2r)-2-[(4-chlorophenyl)sulonyl-[[2-luoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-triluoropentanamide
AKOS005146523
CHEMBL1090771
bms-708163-01
bms 708163
bms-70816301
bms-708163 ,
avagacestat (usan)
D09869
(2r)-2-(n-((4-chlorophenyl)sulfonyl)-n-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide
tq44wwy45q ,
unii-tq44wwy45q
avagacestat [usan:inn]
BCP9000429
bms708163
AKOS016016280
(2r)-5,5,5-trifluoro-2-(n-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl}4-chlorobenzenesulfonamido)pentanamide
BCPP000327
BCP0726000124
NCGC00346504-01
CS-0180
S1262
(2r)-2-[n-[(4-chlorophenyl)sulfonyl]-n-[2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl]amino]-5,5,5-trifluoropentanamide
gtpl6489
SCHEMBL310019
smr004676648
MLS006011074
bms-708163 (avagacestat)
(2r)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide
avagacestat [usan]
avagacestat [inn]
pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2r)-
avagacestat [who-dd]
DTXSID40150811
mfcd13195458
(2r)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-pentanamide
avagacestat, >=98% (hplc)
(2r)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide
AS-75078
MRF-0000009
(r)-2-(4-chloro-n-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)-phenylsulfonamido)-5,5,5-trifluoropentanamide
SW218162-2
avagacestat (bms-708163)
DB11893
BCP01770
(r)-2-((4-chloro-n-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenyl)sulfonamido)-5,5,5-trifluoropentanamide
(2r)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-pentanamide
Q27074630
avagacestat; bms-708163
EX-A2871
pentanamide, 2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-, (2r)-
HMS3884O07
CCG-269860
nsc761217
nsc-761217
(2r)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoranyl-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-tris(fluoranyl)pentanamide
en9 ,
C71464
bdbm50458169
bms-708163;(r)-2-(4-chloro-n-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5,5,5-trifluoropentanamide
A894166

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events were generally mild, occurring more frequently in elderly subjects, with no observed difference between subjects receiving avagacestat and placebo."( A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, R; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2013
)
0.39
" Treatment-emergent serious adverse events were similar across placebo and treatment groups."( Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Albright, C; Andreasen, N; Andreasson, U; Berman, RM; Blennow, K; Brody, M; Colby, S; Coric, V; Dockens, R; Feldman, HH; Pachai, C; Pilcher, G; Portelius, E; Richter, RW; Rollin, L; Salloway, S; Shiovitz, T; Soares, H; Soininen, H; Thein, S; van Dyck, CH, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" We reasoned that an animal model would be suitable for GSI discovery if the pharmacokinetic (PK)/pharmacodynamic (PD) relationship of a compound for Aβ lowering in this model is predictive of that in human."( Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Atchison, K; Becker, SL; Efremov, I; Hallgren, AJ; Lu, Y; Miller, EH; Nolan, CE; Osgood, SM; Pustilnik, LR; Riddell, D; Robshaw, AE; Stepan, AF; Subramanyam, C; Zhang, L, 2011
)
0.37
"The goal of this study was to assess the tolerability profile, pharmacokinetic properties, and effects on pharmacodynamic markers (Aβ, trefoil factor family 3 protein, dual specificity phosphatase 6, and hairy and enhancer of split-1) of single, oral doses of avagacestat in healthy, young, male volunteers."( Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, RC; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38
"The favourable safety profile and pharmacokinetic effects of avagacestat in this study support its continued development, especially in the target population of elderly subjects with mild cognitive impairment or Alzheimer's disease."( A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, R; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2013
)
0.39
"Avagacestat was rapidly absorbed, had a terminal elimination half-life of 38-65 h, and reached a steady-state concentration by day 10 of daily dosing."( A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Albright, CF; Berman, RM; Castaneda, L; Dockens, R; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"A methodology for the accurate calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) assays and its application in supporting microdose absolute bioavailability studies are reported for the first time."( Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
Arnold, ME; Aubry, AF; Bifano, M; Burrell, R; Dockens, R; Easter, J; Gu, H; Jiang, H; Wang, J; Wang, JS; Zeng, J, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"This was a multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study in 8 healthy young men (age, 18-45 years) per dosing panel."( Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, RC; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38
"Avagacestat dosed at 25 and 50 mg daily was relatively well tolerated and had low discontinuation rates."( Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Albright, C; Andreasen, N; Andreasson, U; Berman, RM; Blennow, K; Brody, M; Colby, S; Coric, V; Dockens, R; Feldman, HH; Pachai, C; Pilcher, G; Portelius, E; Richter, RW; Rollin, L; Salloway, S; Shiovitz, T; Soares, H; Soininen, H; Thein, S; van Dyck, CH, 2012
)
0.38
"Amorphous spray-dried dispersions (SDDs) are a key enabling technology for oral solid dosage formulations, used to improve dissolution behaviour and clinical exposure of poorly soluble active pharmaceutical ingredients (APIs)."( Elucidating spray-dried dispersion dissolution mechanisms with focused beam reflectance measurement: contribution of polymer chemistry and particle properties to performance.
Ferreira, AP; Nicholls, D; Nicholson, S; Rawlinson-Malone, CF, 2019
)
0.51
"The objective of this Letter is to report the first (to our knowledge) in vivo proof of concept for a sulfenamide prodrug to orally deliver a poorly soluble drug containing a weakly-acidic NH-acid from a conventional solid dosage formulation."( An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
Clarke, W; Everlof, JG; Guarino, VR; Haskell, R; Lentz, KA; McDonald, I; Olson, RE; Wang, N, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
oxadiazole
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency14.47320.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Presenilin-1Homo sapiens (human)IC50 (µMol)0.00060.00010.23785.6800AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Presenilin-2Homo sapiens (human)IC50 (µMol)0.00060.00010.24355.6800AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Gamma-secretase subunit APH-1BHomo sapiens (human)IC50 (µMol)0.00060.00010.24355.6800AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
NicastrinHomo sapiens (human)IC50 (µMol)0.00060.00010.24355.6800AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Gamma-secretase subunit APH-1AHomo sapiens (human)IC50 (µMol)0.00060.00010.24355.6800AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
Gamma-secretase subunit PEN-2Homo sapiens (human)IC50 (µMol)0.00060.00010.24425.6800AID1383009; AID475563; AID671900; AID754316; AID754317; AID755855; AID755856
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Presenilin-1Homo sapiens (human)ED500.00120.00110.00340.0078AID754313
Presenilin-2Homo sapiens (human)ED500.00120.00110.00340.0078AID754313
Gamma-secretase subunit APH-1BHomo sapiens (human)ED500.00120.00110.00340.0078AID754313
NicastrinHomo sapiens (human)ED500.00120.00110.00340.0078AID754313
Gamma-secretase subunit APH-1AHomo sapiens (human)ED500.00120.00110.00340.0078AID754313
Gamma-secretase subunit PEN-2Homo sapiens (human)ED500.00120.00110.01200.0360AID754313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (107)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityPresenilin-1Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasisPresenilin-1Homo sapiens (human)
cell-cell adhesionPresenilin-1Homo sapiens (human)
autophagosome assemblyPresenilin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPresenilin-1Homo sapiens (human)
blood vessel developmentPresenilin-1Homo sapiens (human)
cell fate specificationPresenilin-1Homo sapiens (human)
somitogenesisPresenilin-1Homo sapiens (human)
neuron migrationPresenilin-1Homo sapiens (human)
positive regulation of receptor recyclingPresenilin-1Homo sapiens (human)
negative regulation of protein phosphorylationPresenilin-1Homo sapiens (human)
positive regulation of protein phosphorylationPresenilin-1Homo sapiens (human)
heart loopingPresenilin-1Homo sapiens (human)
positive regulation of L-glutamate import across plasma membranePresenilin-1Homo sapiens (human)
hematopoietic progenitor cell differentiationPresenilin-1Homo sapiens (human)
astrocyte activation involved in immune responsePresenilin-1Homo sapiens (human)
T cell activation involved in immune responsePresenilin-1Homo sapiens (human)
neural retina developmentPresenilin-1Homo sapiens (human)
protein glycosylationPresenilin-1Homo sapiens (human)
membrane protein ectodomain proteolysisPresenilin-1Homo sapiens (human)
mitochondrial transportPresenilin-1Homo sapiens (human)
DNA damage responsePresenilin-1Homo sapiens (human)
response to oxidative stressPresenilin-1Homo sapiens (human)
Notch receptor processingPresenilin-1Homo sapiens (human)
learning or memoryPresenilin-1Homo sapiens (human)
memoryPresenilin-1Homo sapiens (human)
post-embryonic developmentPresenilin-1Homo sapiens (human)
regulation of gene expressionPresenilin-1Homo sapiens (human)
positive regulation of gene expressionPresenilin-1Homo sapiens (human)
negative regulation of gene expressionPresenilin-1Homo sapiens (human)
regulation of neuron projection developmentPresenilin-1Homo sapiens (human)
protein transportPresenilin-1Homo sapiens (human)
choline transportPresenilin-1Homo sapiens (human)
synaptic vesicle targetingPresenilin-1Homo sapiens (human)
protein processingPresenilin-1Homo sapiens (human)
cerebellum developmentPresenilin-1Homo sapiens (human)
cerebral cortex cell migrationPresenilin-1Homo sapiens (human)
Cajal-Retzius cell differentiationPresenilin-1Homo sapiens (human)
dorsal/ventral neural tube patterningPresenilin-1Homo sapiens (human)
embryonic limb morphogenesisPresenilin-1Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processPresenilin-1Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasisPresenilin-1Homo sapiens (human)
positive regulation of tumor necrosis factor productionPresenilin-1Homo sapiens (human)
amyloid-beta formationPresenilin-1Homo sapiens (human)
intracellular signal transductionPresenilin-1Homo sapiens (human)
locomotionPresenilin-1Homo sapiens (human)
positive regulation of protein import into nucleusPresenilin-1Homo sapiens (human)
regulation of phosphorylationPresenilin-1Homo sapiens (human)
amyloid precursor protein metabolic processPresenilin-1Homo sapiens (human)
amyloid precursor protein catabolic processPresenilin-1Homo sapiens (human)
myeloid dendritic cell differentiationPresenilin-1Homo sapiens (human)
positive regulation of apoptotic processPresenilin-1Homo sapiens (human)
negative regulation of apoptotic processPresenilin-1Homo sapiens (human)
negative regulation of neuron apoptotic processPresenilin-1Homo sapiens (human)
skin morphogenesisPresenilin-1Homo sapiens (human)
positive regulation of glycolytic processPresenilin-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionPresenilin-1Homo sapiens (human)
astrocyte activationPresenilin-1Homo sapiens (human)
regulation of synaptic plasticityPresenilin-1Homo sapiens (human)
thymus developmentPresenilin-1Homo sapiens (human)
neuron developmentPresenilin-1Homo sapiens (human)
skeletal system morphogenesisPresenilin-1Homo sapiens (human)
brain morphogenesisPresenilin-1Homo sapiens (human)
epithelial cell proliferationPresenilin-1Homo sapiens (human)
negative regulation of axonogenesisPresenilin-1Homo sapiens (human)
synapse organizationPresenilin-1Homo sapiens (human)
positive regulation of coagulationPresenilin-1Homo sapiens (human)
T cell receptor signaling pathwayPresenilin-1Homo sapiens (human)
sequestering of calcium ionPresenilin-1Homo sapiens (human)
neuron apoptotic processPresenilin-1Homo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisPresenilin-1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicPresenilin-1Homo sapiens (human)
regulation of resting membrane potentialPresenilin-1Homo sapiens (human)
regulation of canonical Wnt signaling pathwayPresenilin-1Homo sapiens (human)
positive regulation of dendritic spine developmentPresenilin-1Homo sapiens (human)
neuron cellular homeostasisPresenilin-1Homo sapiens (human)
calcium ion transmembrane transportPresenilin-1Homo sapiens (human)
apoptotic signaling pathwayPresenilin-1Homo sapiens (human)
regulation of synaptic vesicle cyclePresenilin-1Homo sapiens (human)
L-glutamate import across plasma membranePresenilin-1Homo sapiens (human)
regulation of postsynapse organizationPresenilin-1Homo sapiens (human)
protein catabolic process at postsynapsePresenilin-1Homo sapiens (human)
cellular response to amyloid-betaPresenilin-1Homo sapiens (human)
negative regulation of core promoter bindingPresenilin-1Homo sapiens (human)
positive regulation of amyloid fibril formationPresenilin-1Homo sapiens (human)
neuron projection maintenancePresenilin-1Homo sapiens (human)
negative regulation of ubiquitin-dependent protein catabolic processPresenilin-1Homo sapiens (human)
negative regulation of apoptotic signaling pathwayPresenilin-1Homo sapiens (human)
calcium ion homeostasisPresenilin-1Homo sapiens (human)
Notch signaling pathwayPresenilin-1Homo sapiens (human)
response to hypoxiaPresenilin-2Homo sapiens (human)
membrane protein ectodomain proteolysisPresenilin-2Homo sapiens (human)
Notch receptor processingPresenilin-2Homo sapiens (human)
protein processingPresenilin-2Homo sapiens (human)
amyloid-beta formationPresenilin-2Homo sapiens (human)
intracellular signal transductionPresenilin-2Homo sapiens (human)
amyloid precursor protein catabolic processPresenilin-2Homo sapiens (human)
regulation of calcium import into the mitochondrionPresenilin-2Homo sapiens (human)
mitochondrion-endoplasmic reticulum membrane tetheringPresenilin-2Homo sapiens (human)
calcium ion homeostasisPresenilin-2Homo sapiens (human)
Notch signaling pathwayPresenilin-2Homo sapiens (human)
protein processingGamma-secretase subunit APH-1BHomo sapiens (human)
Notch receptor processingGamma-secretase subunit APH-1BHomo sapiens (human)
positive regulation of endopeptidase activityGamma-secretase subunit APH-1BHomo sapiens (human)
protein processingGamma-secretase subunit APH-1BHomo sapiens (human)
membrane protein intracellular domain proteolysisGamma-secretase subunit APH-1BHomo sapiens (human)
amyloid-beta formationGamma-secretase subunit APH-1BHomo sapiens (human)
amyloid precursor protein catabolic processGamma-secretase subunit APH-1BHomo sapiens (human)
Notch signaling pathwayGamma-secretase subunit APH-1BHomo sapiens (human)
myeloid cell homeostasisNicastrinHomo sapiens (human)
proteolysisNicastrinHomo sapiens (human)
membrane protein ectodomain proteolysisNicastrinHomo sapiens (human)
dopamine receptor signaling pathwayNicastrinHomo sapiens (human)
glutamate receptor signaling pathwayNicastrinHomo sapiens (human)
Notch signaling pathwayNicastrinHomo sapiens (human)
Notch receptor processingNicastrinHomo sapiens (human)
learning or memoryNicastrinHomo sapiens (human)
positive regulation of endopeptidase activityNicastrinHomo sapiens (human)
protein processingNicastrinHomo sapiens (human)
cerebellum developmentNicastrinHomo sapiens (human)
central nervous system myelinationNicastrinHomo sapiens (human)
adult behaviorNicastrinHomo sapiens (human)
membrane protein intracellular domain proteolysisNicastrinHomo sapiens (human)
amyloid-beta formationNicastrinHomo sapiens (human)
T cell proliferationNicastrinHomo sapiens (human)
amyloid precursor protein metabolic processNicastrinHomo sapiens (human)
amyloid precursor protein biosynthetic processNicastrinHomo sapiens (human)
positive regulation of amyloid precursor protein biosynthetic processNicastrinHomo sapiens (human)
amyloid precursor protein catabolic processNicastrinHomo sapiens (human)
epithelial cell proliferationNicastrinHomo sapiens (human)
neuron apoptotic processNicastrinHomo sapiens (human)
cellular response to calcium ionNicastrinHomo sapiens (human)
regulation of long-term synaptic potentiationNicastrinHomo sapiens (human)
short-term synaptic potentiationNicastrinHomo sapiens (human)
metanephros developmentGamma-secretase subunit APH-1AHomo sapiens (human)
membrane protein ectodomain proteolysisGamma-secretase subunit APH-1AHomo sapiens (human)
Notch receptor processingGamma-secretase subunit APH-1AHomo sapiens (human)
positive regulation of endopeptidase activityGamma-secretase subunit APH-1AHomo sapiens (human)
protein processingGamma-secretase subunit APH-1AHomo sapiens (human)
membrane protein intracellular domain proteolysisGamma-secretase subunit APH-1AHomo sapiens (human)
amyloid-beta formationGamma-secretase subunit APH-1AHomo sapiens (human)
amyloid precursor protein metabolic processGamma-secretase subunit APH-1AHomo sapiens (human)
amyloid precursor protein catabolic processGamma-secretase subunit APH-1AHomo sapiens (human)
Notch signaling pathwayGamma-secretase subunit APH-1AHomo sapiens (human)
membrane protein ectodomain proteolysisGamma-secretase subunit PEN-2Homo sapiens (human)
Notch signaling pathwayGamma-secretase subunit PEN-2Homo sapiens (human)
Notch receptor processingGamma-secretase subunit PEN-2Homo sapiens (human)
positive regulation of endopeptidase activityGamma-secretase subunit PEN-2Homo sapiens (human)
protein processingGamma-secretase subunit PEN-2Homo sapiens (human)
membrane protein intracellular domain proteolysisGamma-secretase subunit PEN-2Homo sapiens (human)
amyloid-beta formationGamma-secretase subunit PEN-2Homo sapiens (human)
amyloid precursor protein metabolic processGamma-secretase subunit PEN-2Homo sapiens (human)
amyloid precursor protein catabolic processGamma-secretase subunit PEN-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
endopeptidase activityPresenilin-1Homo sapiens (human)
aspartic-type endopeptidase activityPresenilin-1Homo sapiens (human)
calcium channel activityPresenilin-1Homo sapiens (human)
protein bindingPresenilin-1Homo sapiens (human)
beta-catenin bindingPresenilin-1Homo sapiens (human)
PDZ domain bindingPresenilin-1Homo sapiens (human)
aspartic endopeptidase activity, intramembrane cleavingPresenilin-1Homo sapiens (human)
cadherin bindingPresenilin-1Homo sapiens (human)
ATPase bindingPresenilin-1Homo sapiens (human)
growth factor receptor bindingPresenilin-1Homo sapiens (human)
protein bindingPresenilin-2Homo sapiens (human)
aspartic endopeptidase activity, intramembrane cleavingPresenilin-2Homo sapiens (human)
protein bindingGamma-secretase subunit APH-1BHomo sapiens (human)
protein-macromolecule adaptor activityGamma-secretase subunit APH-1BHomo sapiens (human)
endopeptidase activator activityGamma-secretase subunit APH-1BHomo sapiens (human)
protein bindingNicastrinHomo sapiens (human)
protein-macromolecule adaptor activityNicastrinHomo sapiens (human)
aspartic endopeptidase activity, intramembrane cleavingNicastrinHomo sapiens (human)
ATPase bindingNicastrinHomo sapiens (human)
growth factor receptor bindingNicastrinHomo sapiens (human)
protein bindingGamma-secretase subunit APH-1AHomo sapiens (human)
enzyme bindingGamma-secretase subunit APH-1AHomo sapiens (human)
protein-macromolecule adaptor activityGamma-secretase subunit APH-1AHomo sapiens (human)
endopeptidase activator activityGamma-secretase subunit APH-1AHomo sapiens (human)
protein bindingGamma-secretase subunit PEN-2Homo sapiens (human)
enzyme bindingGamma-secretase subunit PEN-2Homo sapiens (human)
endopeptidase activator activityGamma-secretase subunit PEN-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (46)

Processvia Protein(s)Taxonomy
smooth endoplasmic reticulumPresenilin-1Homo sapiens (human)
dendritePresenilin-1Homo sapiens (human)
Golgi membranePresenilin-1Homo sapiens (human)
kinetochorePresenilin-1Homo sapiens (human)
nucleusPresenilin-1Homo sapiens (human)
nuclear outer membranePresenilin-1Homo sapiens (human)
nucleoplasmPresenilin-1Homo sapiens (human)
mitochondrionPresenilin-1Homo sapiens (human)
mitochondrial inner membranePresenilin-1Homo sapiens (human)
endoplasmic reticulumPresenilin-1Homo sapiens (human)
endoplasmic reticulum membranePresenilin-1Homo sapiens (human)
smooth endoplasmic reticulumPresenilin-1Homo sapiens (human)
rough endoplasmic reticulumPresenilin-1Homo sapiens (human)
Golgi apparatusPresenilin-1Homo sapiens (human)
centrosomePresenilin-1Homo sapiens (human)
plasma membranePresenilin-1Homo sapiens (human)
cell cortexPresenilin-1Homo sapiens (human)
synaptic vesiclePresenilin-1Homo sapiens (human)
cell surfacePresenilin-1Homo sapiens (human)
membranePresenilin-1Homo sapiens (human)
aggresomePresenilin-1Homo sapiens (human)
cell junctionPresenilin-1Homo sapiens (human)
growth conePresenilin-1Homo sapiens (human)
neuromuscular junctionPresenilin-1Homo sapiens (human)
early endosome membranePresenilin-1Homo sapiens (human)
nuclear membranePresenilin-1Homo sapiens (human)
ciliary rootletPresenilin-1Homo sapiens (human)
azurophil granule membranePresenilin-1Homo sapiens (human)
sarcolemmaPresenilin-1Homo sapiens (human)
presynaptic membranePresenilin-1Homo sapiens (human)
neuron projectionPresenilin-1Homo sapiens (human)
neuronal cell bodyPresenilin-1Homo sapiens (human)
dendritic shaftPresenilin-1Homo sapiens (human)
membrane raftPresenilin-1Homo sapiens (human)
postsynapsePresenilin-1Homo sapiens (human)
glutamatergic synapsePresenilin-1Homo sapiens (human)
protein-containing complexPresenilin-1Homo sapiens (human)
gamma-secretase complexPresenilin-1Homo sapiens (human)
Golgi membranePresenilin-2Homo sapiens (human)
kinetochorePresenilin-2Homo sapiens (human)
nuclear inner membranePresenilin-2Homo sapiens (human)
early endosomePresenilin-2Homo sapiens (human)
endoplasmic reticulumPresenilin-2Homo sapiens (human)
endoplasmic reticulum membranePresenilin-2Homo sapiens (human)
Golgi apparatusPresenilin-2Homo sapiens (human)
centrosomePresenilin-2Homo sapiens (human)
plasma membranePresenilin-2Homo sapiens (human)
synaptic vesiclePresenilin-2Homo sapiens (human)
membranePresenilin-2Homo sapiens (human)
presynaptic membranePresenilin-2Homo sapiens (human)
protein-containing complexPresenilin-2Homo sapiens (human)
gamma-secretase complexPresenilin-2Homo sapiens (human)
Golgi membraneGamma-secretase subunit APH-1BHomo sapiens (human)
endoplasmic reticulum membraneGamma-secretase subunit APH-1BHomo sapiens (human)
plasma membraneGamma-secretase subunit APH-1BHomo sapiens (human)
endosome membraneGamma-secretase subunit APH-1BHomo sapiens (human)
membraneGamma-secretase subunit APH-1BHomo sapiens (human)
transport vesicleGamma-secretase subunit APH-1BHomo sapiens (human)
gamma-secretase complexGamma-secretase subunit APH-1BHomo sapiens (human)
endoplasmic reticulumGamma-secretase subunit APH-1BHomo sapiens (human)
Golgi membraneNicastrinHomo sapiens (human)
lysosomal membraneNicastrinHomo sapiens (human)
early endosomeNicastrinHomo sapiens (human)
endoplasmic reticulumNicastrinHomo sapiens (human)
endoplasmic reticulum membraneNicastrinHomo sapiens (human)
Golgi apparatusNicastrinHomo sapiens (human)
plasma membraneNicastrinHomo sapiens (human)
focal adhesionNicastrinHomo sapiens (human)
synaptic vesicleNicastrinHomo sapiens (human)
endosome membraneNicastrinHomo sapiens (human)
membraneNicastrinHomo sapiens (human)
azurophil granule membraneNicastrinHomo sapiens (human)
sarcolemmaNicastrinHomo sapiens (human)
melanosomeNicastrinHomo sapiens (human)
presynaptic membraneNicastrinHomo sapiens (human)
extracellular exosomeNicastrinHomo sapiens (human)
gamma-secretase complexNicastrinHomo sapiens (human)
plasma membraneNicastrinHomo sapiens (human)
Golgi membraneGamma-secretase subunit APH-1AHomo sapiens (human)
early endosomeGamma-secretase subunit APH-1AHomo sapiens (human)
endoplasmic reticulumGamma-secretase subunit APH-1AHomo sapiens (human)
endoplasmic reticulum membraneGamma-secretase subunit APH-1AHomo sapiens (human)
Golgi apparatusGamma-secretase subunit APH-1AHomo sapiens (human)
plasma membraneGamma-secretase subunit APH-1AHomo sapiens (human)
synaptic vesicleGamma-secretase subunit APH-1AHomo sapiens (human)
endosome membraneGamma-secretase subunit APH-1AHomo sapiens (human)
membraneGamma-secretase subunit APH-1AHomo sapiens (human)
Golgi cisterna membraneGamma-secretase subunit APH-1AHomo sapiens (human)
presynaptic membraneGamma-secretase subunit APH-1AHomo sapiens (human)
gamma-secretase complexGamma-secretase subunit APH-1AHomo sapiens (human)
endoplasmic reticulumGamma-secretase subunit APH-1AHomo sapiens (human)
Golgi membraneGamma-secretase subunit PEN-2Homo sapiens (human)
endoplasmic reticulumGamma-secretase subunit PEN-2Homo sapiens (human)
endoplasmic reticulum membraneGamma-secretase subunit PEN-2Homo sapiens (human)
Golgi apparatusGamma-secretase subunit PEN-2Homo sapiens (human)
plasma membraneGamma-secretase subunit PEN-2Homo sapiens (human)
endosome membraneGamma-secretase subunit PEN-2Homo sapiens (human)
membraneGamma-secretase subunit PEN-2Homo sapiens (human)
Golgi cisterna membraneGamma-secretase subunit PEN-2Homo sapiens (human)
presynaptic membraneGamma-secretase subunit PEN-2Homo sapiens (human)
gamma-secretase complexGamma-secretase subunit PEN-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (101)

Assay IDTitleYearJournalArticle
AID755848Oxidative metabolism in rat liver microsomes assessed as compound remaining2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671906Thermodynamic solubility of the compound at pH 6.52012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755849Oxidative metabolism in dog liver microsomes assessed as compound remaining2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID755843Glucuronidation metabolism in human liver microsomes assessed as compound remaining2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671926Cmax in 129/sve mouse plasma at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755854Selctivity ratio of IC50 for partially purified human gamma-secretase-mediated cleavage of notch fusion protein to IC50 for partially purified human gamma-secretase-mediated cleavage of MBP-APPc125Sw fusion protein2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID672066Antialzheimer activity in 129/sve mouse assessed as reduction in amyloid beta40 level in CSF at 30 mg/kg, po administered as single dose measured at 2 hrs by ELISA relative to vehicle treated control2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755852Inhibition of gamma-secretase in CHO cells assessed expressing NotchdeltaE assessed as inhibition of notch cleavage after overnight incubation by luciferase reporter gene assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID1650829Drug concentration in Beagle dog plasma at 3 mg/kg, po measured at 24 hrs2020Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID1383005Selectivity ratio of IC50 for inhibition of gamma-secretase (unknown origin) assessed as notch cleavage to IC50 for inhibition of gamma-secretase (unknown origin) assessed as APP cleavage2018European journal of medicinal chemistry, Mar-25, Volume: 148Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead.
AID1650826Cmax in Beagle dog at 3 mg/kg, po2020Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID1383009Inhibition of gamma-secretase in human H4-8Sw cells assessed as reduction in amyloid beta (1 to 42) formation2018European journal of medicinal chemistry, Mar-25, Volume: 148Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead.
AID755812Reduction in amyloid beta (x to 40) in FVB mouse cortex at 3 mg/kg, po administered as single dose measured at 3 hrs2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671935Tmax in 129/sve mouse cerebrospinal fluid at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671927Tmax in 129/sve mouse plasma at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755847Oxidative metabolism in human liver microsomes assessed as compound remaining2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671929Cmax in 129/sve mouse brain at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID672065Antialzheimer activity in 129/sve mouse assessed as reduction in amyloid beta42 level in brain at 30 mg/kg, po administered as single dose measured at 4 hrs by ELISA relative to vehicle treated control2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755846Glucuronidation metabolism in mouse liver microsomes assessed as compound remaining2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID630268Selectivity for gamma secretase over notch cleavage2011Journal of medicinal chemistry, Nov-24, Volume: 54, Issue:22
Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors.
AID754317Inhibition of gamma-secretase in human IMR32 cell membrane using Notch as substrate after 2 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID671928AUC (0 to 18 hrs) in 129/sve mouse plasma at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID672071Fraction unbound in 129/sve mouse plasma at 30 mg/kg, po administered as single dose2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671934Cmax in 129/sve mouse cerebrospinal fluid at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755851Selctivity ratio of ED50 for gamma-secretase in CHO cells assessed expressing NotchdeltaE assessed as inhibition of notch cleavage to ED50 for gamma-secretase in CHO cells assessed expressing APPSw assessed as inhibition of amyloid beta(1 to x) secretion2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID755844Glucuronidation metabolism in rat liver microsomes assessed as compound remaining2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671903Apparent total intrinsic clearance in human liver microsomes assessed per million cells2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755813Reduction in amyloid beta (x to 40) in FVB mouse cortex at 1 mg/kg, po administered as single dose measured at 3 hrs2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID755810Reduction in amyloid beta (x to 40) in FVB mouse cortex at 10 mg/kg, po administered as single dose measured at 3 hrs2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671913Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671902Apparent total intrinsic clearance in human hepatocytes assessed per million cells2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671931AUC (0 to 18 hrs) in 129/sve mouse brain at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671908Efflux ratio of apparent permeability from basal to apical side to apical to basal side of MDCK cells expressing human P-gp2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671905Kinetic solubility of the solubility of the compound at pH 6.52012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475567Inhibition of gamma secretase-mediated total amyloid beta production in healthy human CSF at 200 mg/kg administered as single dose2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID697324Inhibition of gamma-secretase2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as γ-secretase inhibitors.
AID671901Selectivity for human gamma-seretase over notch signalling protein2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671910Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755856Inhibition of partially purified human gamma-secretase-mediated cleavage of MBP-APPc125Sw fusion protein measured after overnight incubation by ELISA2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID1650827AUC (0 to 24 hrs) in Beagle dog at 3 mg/kg, po2020Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID672067Antialzheimer activity in 129/sve mouse assessed as reduction in amyloid beta40 level in plasma at 30 mg/kg, po administered as single dose measured at 0.5 hrs by ELISA relative to vehicle treated control2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID755855Inhibition of partially purified human gamma-secretase-mediated cleavage of notch fusion protein measured after overnight incubation by ELISA2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID754313Inhibition of gamma-secretase in HEK293 cells after overnight incubation by Western blotting analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID671930Tmax in 129/sve mouse brain at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671912Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID672064Antialzheimer activity in 129/sve mouse assessed as reduction in amyloid beta40 level in brain at 30 mg/kg, po administered as single dose measured at 4 hrs by ELISA relative to vehicle treated control2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475565Half life in healthy human at 200 mg/kg administered as single dose2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID755811Reduction in amyloid beta (x to 40) in FVB mouse cortex at 30 mg/kg, po administered as single dose measured at 3 hrs2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID755853Inhibition of gamma-secretase in CHO cells assessed expressing APPSw assessed as inhibition of amyloid beta(1 to x) secretion after overnight incubation by ELISA2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID671936AUC (0 to 18 hrs) in 129/sve mouse cerebrospinal fluid at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID754315Ratio of IC50 for gamma-secretase in human IMR32 cells using Notch as substrate to IC50 for gamma-secretase in human IMR-32 cells using APP as substrate2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID755850Oxidative metabolism in mouse liver microsomes assessed as compound remaining2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID1650828Tmax in Beagle dog at 3 mg/kg, po2020Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID672072Fraction unbound in 129/sve mouse brain at 30 mg/kg, po administered as single dose2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475563Inhibition of human gamma secretase-mediated amyloid beta (1 to 40) production expressed in human H4 cells2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID671904Apparent permeability from apical to basal side of dog RRCK cells2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID1650823Aqueous solubility of compound at pH 6.52020Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
AID671907Thermodynamic solubility of the compound at pH 7.42012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475566Inhibition of gamma secretase-mediated total amyloid beta production in healthy human plasma at 200 mg/kg administered as single dose2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID671911Inhibition of CYP2C19 in human liver microsomes using (S)-mephenytoin as substrate2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID475564Selectivity for human gamma secretase-mediated amyloid beta (1 to 40) production over human gamma secretase-mediated notch processing2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
AID671909Inhibition of CYP1A2 in human liver microsomes using tacrine as substrate2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671933Ratio of unbound fraction in brain to unbound fraction in plasma in 129/sve mouse at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671900Inhibition of gamma secretase-mediated amyloid beta42 production in human H4 cells expressing human APP swedish mutant2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID671932Ratio of drug level in brain to plasma in 129/sve mouse at 30 mg/kg, po administered as single dose by LC-MS/MS analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
AID754314Inhibition of gamma-secretase in CHO cells after overnight incubation by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID754316Inhibition of gamma-secretase in human IMR32 cell membrane using APP as substrate after 2 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID754312Ratio of IC50 for gamma-secretase in CHO cells using Notch as substrate to ED50 for gamma-secretase in HEK293 cells using APP as substrate2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Discovery of a novel [3.2.1] benzo fused bicyclic sulfonamide-pyrazoles as potent, selective and efficacious γ-secretase inhibitors.
AID755845Glucuronidation metabolism in dog liver microsomes assessed as compound remaining2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (2.17)29.6817
2010's34 (73.91)24.3611
2020's11 (23.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.94 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index6.26 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (10.87%)5.53%
Reviews4 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (2.17%)0.25%
Other36 (78.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Mild to Moderate Alzheimer's Disease [NCT00810147]Phase 2209 participants (Actual)Interventional2009-02-28Completed
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer's Disease [NCT00890890]Phase 2263 participants (Actual)Interventional2009-05-31Terminated
A Study of the Effect of Concomitant Administration of Ketoconazole or Fluconazole on the Pharmacokinetics of BMS-708163 in Healthy Subjects [NCT00860275]Phase 130 participants (Actual)Interventional2009-04-30Completed
Randomized, Double-Blinded, Placebo-Controlled, Open Label Positive- Controlled, Four-Way Crossover Study of the Electrocardiographic Effects of BMS-708163 in Healthy Subjects [NCT00979316]Phase 162 participants (Actual)Interventional2009-09-30Completed
Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 125 mg in Healthy Japanese and Non-Japanese Subjects [NCT01057030]Phase 122 participants (Actual)Interventional2010-03-31Completed
Randomized, Placebo-controlled, Double-blind, Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163 in Healthy Young Male and Elderly Male and Female Chinese Subjects [NCT01079819]Phase 132 participants (Actual)Interventional2010-04-30Completed
Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Japanese Subjects and a Comparison to Healthy Elderly Japanese Subjects [NCT00828646]Phase 132 participants (Actual)Interventional2008-10-31Completed
Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail [NCT00726726]Phase 122 participants (Actual)Interventional2008-08-31Completed
A Bioavailability Study of Four Experimental BMS-708163 Formulations Relative to Solubilized Capsule Formulation in Healthy Young Male Subjects [NCT00901498]Phase 136 participants (Actual)Interventional2009-05-31Completed
A Study of the Effect of Concomitant Administration of Multiple Doses of BMS-708163 on the Pharmacokinetics of Galantamine in Healthy Subjects [NCT01039194]Phase 118 participants (Actual)Interventional2010-01-31Completed
A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects [NCT01042314]Phase 118 participants (Actual)Interventional2010-01-31Completed
A Study of the Effect of Concomitant Administration of Rifampin on the Pharmacokinetics of BMS-708163 in Healthy Subjects [NCT01002079]Phase 120 participants (Actual)Interventional2010-08-31Completed
Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Subjects and a Comparison to Elderly Male and Female Subjects [NCT01454115]Phase 1116 participants (Actual)Interventional2007-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]